Norwegian researchers gave anti-CD38 antibody daratumumab to 10 women with moderate to severe ME/CFS.
Six showed marked improvement, with physical function scores more than doubling and step counts tripling.
No serious side effects were reported.
www.frontiersin.org/journals/med...
Six showed marked improvement, with physical function scores more than doubling and step counts tripling.
No serious side effects were reported.
www.frontiersin.org/journals/med...
Frontiers | Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) -a clinical pilot study
Background: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) entails low quality of life for patients and massive societal costs. There is an urge...
www.frontiersin.org
June 24, 2025 at 12:56 PM
Norwegian researchers gave anti-CD38 antibody daratumumab to 10 women with moderate to severe ME/CFS.
Six showed marked improvement, with physical function scores more than doubling and step counts tripling.
No serious side effects were reported.
www.frontiersin.org/journals/med...
Six showed marked improvement, with physical function scores more than doubling and step counts tripling.
No serious side effects were reported.
www.frontiersin.org/journals/med...
You can now hear a preview of the Star Celebration character song on the official GBF music site! Be warned, the default volume is quite loud.
song.granbluefantasy.jp/cd38/
song.granbluefantasy.jp/cd38/
May 1, 2026 at 8:41 AM
You can now hear a preview of the Star Celebration character song on the official GBF music site! Be warned, the default volume is quite loud.
song.granbluefantasy.jp/cd38/
song.granbluefantasy.jp/cd38/
Anti-CD38-Antikörper Daratumumab bei myalgischer Enzephalomyelitis/chronischem Erschöpfungssyndrom – eine klinische Pilotstudie “ bestand darin, Autoantikörper-sezernierende B-Zellen zu zerstören, um so den Blutfluss zu verbessern, Vorlast und Hypoxie zu verringern und die
July 19, 2025 at 1:31 PM
Anti-CD38-Antikörper Daratumumab bei myalgischer Enzephalomyelitis/chronischem Erschöpfungssyndrom – eine klinische Pilotstudie “ bestand darin, Autoantikörper-sezernierende B-Zellen zu zerstören, um so den Blutfluss zu verbessern, Vorlast und Hypoxie zu verringern und die
One focus of the Int. MECFS Conference 12./13.5. at Charité will be Clinical trials targeting autoantibodies and immune dysregulation including CD38, CD20 and C19 antibodies, immunoadsorption, IVIG, and rapamycin.
You can join the event via free livestream
events.mecfs-research.org/en/events/co...
You can join the event via free livestream
events.mecfs-research.org/en/events/co...
May 2, 2025 at 5:31 PM
One focus of the Int. MECFS Conference 12./13.5. at Charité will be Clinical trials targeting autoantibodies and immune dysregulation including CD38, CD20 and C19 antibodies, immunoadsorption, IVIG, and rapamycin.
You can join the event via free livestream
events.mecfs-research.org/en/events/co...
You can join the event via free livestream
events.mecfs-research.org/en/events/co...
In #CD38, I endorse the incumbent Shahana Hanif. Another strong voice for transportation, she supported the Arrow Linen rezoning and City of Yes. She is facing a primary challenger funded, in part, by Republican donors.
June 13, 2025 at 8:11 PM
In #CD38, I endorse the incumbent Shahana Hanif. Another strong voice for transportation, she supported the Arrow Linen rezoning and City of Yes. She is facing a primary challenger funded, in part, by Republican donors.
5) Instead of CD20, plasma cells express the CD38 protein on their surface. By using daratumumab, which targets CD38, researchers hope to kill these plasma cells and stop the production of autoantibodies.
Results from the pilot study were promising:
Results from the pilot study were promising:
Frontiers | Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study
BackgroundMyalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) entails low quality of life for patients and massive societal costs. There is an urgent...
www.frontiersin.org
January 13, 2026 at 8:48 AM
5) Instead of CD20, plasma cells express the CD38 protein on their surface. By using daratumumab, which targets CD38, researchers hope to kill these plasma cells and stop the production of autoantibodies.
Results from the pilot study were promising:
Results from the pilot study were promising:
This is quite something: a second clinical trial targeting the CD38 receptor on plasma cells (apparently, it's also on some B cells). The other one is the daratumumab trial by Fluge & Mella in Norway (which is a different monoclonal antibody targeting the same CD38 receptor).
5) Scheibenbogen said they have funding for the plasma/CD38 study through private funding and a foundation. Sanofi owns the medication they want to trial (so the drug is probably Isatuximab = Sarclisa) and they are interested in testing it further with them.
September 26, 2025 at 3:03 PM
This is quite something: a second clinical trial targeting the CD38 receptor on plasma cells (apparently, it's also on some B cells). The other one is the daratumumab trial by Fluge & Mella in Norway (which is a different monoclonal antibody targeting the same CD38 receptor).
Dies zeigte eindrucksvoll die ANDROMEDA-Studie. Diese wurde vor einigen Jahren hochrangig publiziert. www.nejm.org/doi/full/10....
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis | NEJM
Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition
of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab,
a human CD38-targeting ant...
www.nejm.org
November 20, 2024 at 3:15 PM
Dies zeigte eindrucksvoll die ANDROMEDA-Studie. Diese wurde vor einigen Jahren hochrangig publiziert. www.nejm.org/doi/full/10....
2) Not entirely sure which drug this refers to, but Scheibenbogen previously talked about doing a trial targeting plasma cells that produce antibodies, so it could be Isatuximab (which targets the cell marker CD38, the same as Daratumumab).
December 17, 2025 at 3:02 PM
2) Not entirely sure which drug this refers to, but Scheibenbogen previously talked about doing a trial targeting plasma cells that produce antibodies, so it could be Isatuximab (which targets the cell marker CD38, the same as Daratumumab).
Widespread deployment of the human CD38 ADP-ribosyl cyclase fold in antibacterial and anti-eukaryotic polymorphic toxins - Journal of Biological Chemistry www.jbc.org/article/S002...
Widespread deployment of the human CD38 ADP-ribosyl cyclase fold in antibacterial and anti-eukaryotic polymorphic toxins
Bacterial polymorphic toxins are modular weapons that mediate intermicrobial competition
and host interactions by delivering diverse cytotoxic domains through specialized
secretion systems. Here, we i...
www.jbc.org
October 29, 2025 at 6:44 AM
Widespread deployment of the human CD38 ADP-ribosyl cyclase fold in antibacterial and anti-eukaryotic polymorphic toxins - Journal of Biological Chemistry www.jbc.org/article/S002...
Third, the very promising data from Oystein Fluge, who showed pilot data with daratumumab (anti-CD38, depleting plasma cells), which improved symptoms in 6/10 ME/CFS patients. Really looking forward to the follow-up study! 4/7
May 13, 2025 at 2:32 PM
Third, the very promising data from Oystein Fluge, who showed pilot data with daratumumab (anti-CD38, depleting plasma cells), which improved symptoms in 6/10 ME/CFS patients. Really looking forward to the follow-up study! 4/7
Anti-CD38 therapies in antibody mediated rejection
Tristan De Natte from Rouen for Ottawa #NephGR
youtu.be/83ym-Is7T4E?...
#Transplant #NephSky
Tristan De Natte from Rouen for Ottawa #NephGR
youtu.be/83ym-Is7T4E?...
#Transplant #NephSky
Anti-CD38 therapies in antibody-mediated rejection with Dr Tristan De Natte
YouTube video by Ottawa Nephrology
youtu.be
December 16, 2025 at 2:44 AM
Anti-CD38 therapies in antibody mediated rejection
Tristan De Natte from Rouen for Ottawa #NephGR
youtu.be/83ym-Is7T4E?...
#Transplant #NephSky
Tristan De Natte from Rouen for Ottawa #NephGR
youtu.be/83ym-Is7T4E?...
#Transplant #NephSky
Great study by the Rezvani lab exploring the relationship between the immunological synapse and NK-CAR function in response to AML. One outstanding question - with a CD38 CAR, how many cord-blood derived CAR-NK cells are undergoing fratricide? A CD38 KO could preserve NK #s and enhance NK function.
Overcoming CD226-related immune evasion in AML with CD38 CAR-engineered NK cells
www.cell.com/cell-reports...
www.cell.com/cell-reports...
January 5, 2025 at 5:19 PM
Great study by the Rezvani lab exploring the relationship between the immunological synapse and NK-CAR function in response to AML. One outstanding question - with a CD38 CAR, how many cord-blood derived CAR-NK cells are undergoing fratricide? A CD38 KO could preserve NK #s and enhance NK function.
2) Some of the most in-depth studies on B-cells in ME/CFS were done by her group (I recently re-read them when writing an overview of findings in the immune system).
Here's an example where they found increased expression of CD38:
pubmed.ncbi.nlm.nih....
Here's an example where they found increased expression of CD38:
pubmed.ncbi.nlm.nih....
August 31, 2026 at 8:22 AM
2) Some of the most in-depth studies on B-cells in ME/CFS were done by her group (I recently re-read them when writing an overview of findings in the immune system).
Here's an example where they found increased expression of CD38:
pubmed.ncbi.nlm.nih....
Here's an example where they found increased expression of CD38:
pubmed.ncbi.nlm.nih....
Targeting the CD38-NAD+ axis disrupts Tregs metabolism in the TME, destabilizes intratumoral Tregs, and boosts antitumor immunity
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
CD38-mediated metabolic reprogramming promotes the stability and suppressive function of regulatory T cells in tumor
Targeting the CD38-NAD+ axis disrupts Tregs metabolism in the TME, destabilizes intratumoral Tregs, and boosts antitumor immunity.
www.science.org
March 21, 2025 at 6:26 PM
Targeting the CD38-NAD+ axis disrupts Tregs metabolism in the TME, destabilizes intratumoral Tregs, and boosts antitumor immunity
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
CD38 expression by neonatal human naïve CD4+ T cells shapes their distinct metabolic and tolerogenic properties @jci.org @ucsfmedicine.bsky.social
www.jci.org/articles/vie...
www.jci.org/articles/vie...
February 26, 2026 at 9:57 PM
CD38 expression by neonatal human naïve CD4+ T cells shapes their distinct metabolic and tolerogenic properties @jci.org @ucsfmedicine.bsky.social
www.jci.org/articles/vie...
www.jci.org/articles/vie...
4) With this new info, they would look to test drugs that deplete B-cells (targeting CD20 or CD19) or plasma cells (targeting CD38).
Her group is ambitious and wants to do both trials in parallel.
Her group is ambitious and wants to do both trials in parallel.
September 25, 2025 at 3:01 PM
4) With this new info, they would look to test drugs that deplete B-cells (targeting CD20 or CD19) or plasma cells (targeting CD38).
Her group is ambitious and wants to do both trials in parallel.
Her group is ambitious and wants to do both trials in parallel.
2 zusätzliche Jahre ohne Hilfe sind für #MEcfs #LC Betroffene ein nicht aushaltbarer Zeitraum.
Ich sehe bisher keinerlei Verbesserungen, auch weil informierte Ärzt*innen fehlen und Bürokratie Hilfe verhindert.
(Schade, daß Frau Scheibenbogen die Betroffenen und Interessierten auf Bluesky vergißt!)
Ich sehe bisher keinerlei Verbesserungen, auch weil informierte Ärzt*innen fehlen und Bürokratie Hilfe verhindert.
(Schade, daß Frau Scheibenbogen die Betroffenen und Interessierten auf Bluesky vergißt!)
Carmen Scheibenbogen on X: "Diese Bundespressekonferenz ist 2 Jahre her! Inzwischen wissen wir deutlich mehr über ME/CFS u.a. dank der vom BMBF geförderten #NKSG-Studien. Wir kennen vielversprechende Behandlungsansätze! Was jetzt fehlt: weitere Förderung für Medikamentenstudien u.a. mit CD19, CD38 mAb!" / X
Diese Bundespressekonferenz ist 2 Jahre her! Inzwischen wissen wir deutlich mehr über ME/CFS u.a. dank der vom BMBF geförderten #NKSG-Studien. Wir kennen vielversprechende Behandlungsansätze! Was jetzt fehlt: weitere Förderung für Medikamentenstudien u.a. mit CD19, CD38 mAb!
x.com
July 13, 2025 at 9:58 AM
6) This is a bit curious, as the Norwegian group of Fluge and Mella is already doing a trial of Daratumumab, a drug that also targets CD38 cells. But perhaps it's good that different research groups are thinking in the same direction.
September 25, 2025 at 3:01 PM
6) This is a bit curious, as the Norwegian group of Fluge and Mella is already doing a trial of Daratumumab, a drug that also targets CD38 cells. But perhaps it's good that different research groups are thinking in the same direction.
The global spread of high pathogenicity avian influenza (HPAI) threatens poultry, livelihoods, and public health.
@FAO.org and @WOAH.org’s updated Global Strategy for HPAI outlines a #OneHealth approach to prevention and control.
📖 Read more 🔗 doi.org/10.4060/cd38...
#AnimalHealth
@FAO.org and @WOAH.org’s updated Global Strategy for HPAI outlines a #OneHealth approach to prevention and control.
📖 Read more 🔗 doi.org/10.4060/cd38...
#AnimalHealth
February 28, 2025 at 4:04 PM
The global spread of high pathogenicity avian influenza (HPAI) threatens poultry, livelihoods, and public health.
@FAO.org and @WOAH.org’s updated Global Strategy for HPAI outlines a #OneHealth approach to prevention and control.
📖 Read more 🔗 doi.org/10.4060/cd38...
#AnimalHealth
@FAO.org and @WOAH.org’s updated Global Strategy for HPAI outlines a #OneHealth approach to prevention and control.
📖 Read more 🔗 doi.org/10.4060/cd38...
#AnimalHealth
CD38 modulates cytokine secretion by NK cells through Sirt1/NF-κB signaling pathway
www.nature.com/articles/s41...
www.nature.com/articles/s41...
November 20, 2024 at 11:31 PM
CD38 modulates cytokine secretion by NK cells through Sirt1/NF-κB signaling pathway
www.nature.com/articles/s41...
www.nature.com/articles/s41...
So weit, so kompliziert. Aber es wird noch anspruchsvoller.
Das fehlgefaltete Eiweiß wird bei der AL-Amyloidose von sogenannten CD38-positiven Plasmazellen im Knochenmark produziert. Die gleichen Zellen, die auch für das Multiple Myelom verantwortlich sind.
Das fehlgefaltete Eiweiß wird bei der AL-Amyloidose von sogenannten CD38-positiven Plasmazellen im Knochenmark produziert. Die gleichen Zellen, die auch für das Multiple Myelom verantwortlich sind.
November 20, 2024 at 3:15 PM
So weit, so kompliziert. Aber es wird noch anspruchsvoller.
Das fehlgefaltete Eiweiß wird bei der AL-Amyloidose von sogenannten CD38-positiven Plasmazellen im Knochenmark produziert. Die gleichen Zellen, die auch für das Multiple Myelom verantwortlich sind.
Das fehlgefaltete Eiweiß wird bei der AL-Amyloidose von sogenannten CD38-positiven Plasmazellen im Knochenmark produziert. Die gleichen Zellen, die auch für das Multiple Myelom verantwortlich sind.
Targeting CD38 immunometabolic checkpoint improves metabolic fitness and cognition in a mouse model of #Alzheimer’s disease @natcomms.nature.com
www.nature.com/articles/s41...
www.nature.com/articles/s41...
April 21, 2025 at 2:24 AM
Targeting CD38 immunometabolic checkpoint improves metabolic fitness and cognition in a mouse model of #Alzheimer’s disease @natcomms.nature.com
www.nature.com/articles/s41...
www.nature.com/articles/s41...
5) Scheibenbogen said they have funding for the plasma/CD38 study through private funding and a foundation. Sanofi owns the medication they want to trial (so the drug is probably Isatuximab = Sarclisa) and they are interested in testing it further with them.
September 25, 2025 at 3:01 PM
5) Scheibenbogen said they have funding for the plasma/CD38 study through private funding and a foundation. Sanofi owns the medication they want to trial (so the drug is probably Isatuximab = Sarclisa) and they are interested in testing it further with them.